Pharmacogenetic Approaches to Personalized SSRI Therapy
DOI:
https://doi.org/10.5195/pur.2026.192Abstract
A complicated interaction of pharmacokinetic (PK), pharmacodynamic (PD), genetic, and epigenetic factors influences inter-individual variability in response to selective serotonin reuptake inhibitors (SSRIs). This review summarizes recent findings in antidepressant pharmacogenetics, emphasizing the functions of important pharmacodynamic loci (SLC6A4, HTR2A, BDNF, ABCB1) and metabolic genes (CYP2C19, CYP2D6) in regulating drug exposure, efficacy, and tolerability. Evidence from observational studies and previous reports suggests that pharmacogenomic-guided therapy may improve treatment outcomes, especially for individuals with abnormal metabolic profiles or treatment resistance. Major obstacles to clinical translation include small effect sizes, population-specific heterogeneity, retrospective studies, and uneven integration with therapeutic drug monitoring. Additional implementation barriers include workflow integration, patient access, cost, and clinical education. To optimize the clinical impact of precision psychiatry, future research should focus on prospective, multicenter trials with diverse populations, standardized clinical decision frameworks, and integration of polygenic, epigenetic, and environmental data. This review investigates whether integrating pharmacogenomic information into SSRI prescribing can enhance treatment outcomes and reduce adverse events.
References
Campos, Adrian I., Enda M. Byrne, Brittany L. Mitchell, et al. 2022. “Impact of CYP2C19 Metaboliser Status on SSRI Response: A Retrospective Study of 9500 Participants of the Australian Genetics of Depression Study.” The Pharmacogenomics Journal 22 (2): 130–35. https://doi.org/10.1038/s41397-022-00267-7.
Grant, Caroline W., Karina Delaney, Linsey E. Jackson, et al. 2025. “Comprehensive Characterization of Antidepressant Pharmacogenetics: A Systematic Review of Studies in Major Depressive Disorder.” Clinical and Translational Science 18 (6): e70255. https://doi.org/10.1111/cts.70255.
Jameson, Adam, Beth Fylan, Greg C. Bristow, et al. 2021. “What Are the Barriers and Enablers to the Implementation of Pharmacogenetic Testing in Mental Health Care Settings?” Frontiers in Genetics 12 (September). https://doi.org/10.3389/fgene.2021.740216.
Lorvellec, Marie-Agnès, Gilles Sipahimalani, Bertrand Lahutte, Hervé Delacour, Antoine Baldacci, and Emeric Saguin. 2024. “Pharmacogenetics Testing for Poor Response to Antidepressants: A Transnosographic Case Series.” Frontiers in Pharmacology 15 (October). https://doi.org/10.3389/fphar.2024.1440523.
Murphy, Greer M., Charlotte Kremer, Heidi E. Rodrigues, and Alan F. Schatzberg. 2003. “Pharmacogenetics of Antidepressant Medication Intolerance.” American Journal of Psychiatry 160 (October): 1830–35. https://doi.org/10.1176/appi.ajp.160.10.1830.
Porcelli, Stefano, Antonio Drago, Chiara Fabbri, Sara Gibiino, Raffaella Calati, and Alessandro Serretti. 2011. “Pharmacogenetics of Antidepressant Response.” Journal of Psychiatry and Neuroscience 36 (2): 87–113. https://doi.org/10.1503/jpn.100059.
Radosavljevic, Milica, Dubravka Svob Strac, Jasna Jancic, and Janko Samardzic. 2023. “The Role of Pharmacogenetics in Personalizing the Antidepressant and Anxiolytic Therapy.” Genes 14 (5): 1095. https://doi.org/10.3390/genes14051095.
Sreeja, V., Anju Jose, Shashikant Patel, Bindu Menon, K. V. Athira, and Sumana Chakravarty. 2024. “Pharmacogenetics of Selective Serotonin Reuptake Inhibitors (SSRI): A Serotonin Reuptake Transporter (SERT)-Based Approach.” Neurochemistry International 173 (February): 105672. https://doi.org/10.1016/j.neuint.2023.105672.
Xu, Lei, Liyin Li, Qiutang Wang, Bing Pan, Leilei Zheng, and Zheng Lin. 2024. “Effect of Pharmacogenomic Testing on the Clinical Treatment of Patients with Depressive Disorder: A Randomized Clinical Trial.” Journal of Affective Disorders 359 (August): 117–24. https://doi.org/10.1016/j.jad.2024.05.063.
Zhang, Ying, and Weihua Yue. 2025. “Optimization of Antidepressant Treatment by Pharmacogenomics: A Case Report.” BMC Psychiatry 25 (1): 34. https://doi.org/10.1186/s12888-025-06481-4.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Aadi Balsaraf

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
- Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
- The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
- Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site;
- The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
- Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
- The Author represents and warrants that:
- the Work is the Author’s original work;
- the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
- the Work is not pending review or under consideration by another publisher;
- the Work has not previously been published;
- the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
- the Work contains no libel, invasion of privacy, or other unlawful matter.
- The Author agrees to indemnify and hold Publisher harmless from Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.
- The Author agrees to digitally sign the Publisher’s final formatted PDF version of the Work.
